SEC Comment Letter 0000000000-23-001525 to Paranovus Entertainment Technology Ltd. (PAVS) (CIK 0001751876) (PAVS)
Paranovus Entertainment Technology Ltd. (PAVS) (CIK 0001751876)
Date: Feb. 14, 2023 · CIK: 0001751876 · Accession: 0000000000-23-001525
AI Filing Summary & Sentiment
File numbers found in text: 001-39098
Letter
United States securities and exchange commission logo February 14, 2023 Xuezhu Wang Chief Executive Officer Happiness Development Group Limited No. 11, Dongjiao East Road, Shuangxi, Shunchang, Nanping City Fujian Province, People’s Republic of China Re:Happiness Development Group Limited Annual Report on Form 20-F for the Fiscal Year Ended March 31, 2022 Response dated February 8, 2023 File No. 001-39098 Dear Xuezhu Wang: We have reviewed your February 8, 2023 response to our comment letter and have the following comment. In our comment, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this comment, we may have additional comments. Unless we note otherwise, our references to prior comments are to comments in our February 2, 2023 letter. Correspondence dated February 8, 2023 Part I Item 4. Information on the Company B. Business Overview, page 9 1.We note your response to comment 8 and reissue in part. Please revise your proposed disclosure to explain why you believe you and your PRC subsidiaries are not required to obtain permission or approval for the listing or trading of Class A ordinary shares in foreign stock exchanges from the CSRC.
FirstName LastNameXuezhu Wang Comapany NameHappiness Development Group Limited February 14, 2023 Page 2 FirstName LastName Xuezhu Wang Happiness Development Group Limited February 14, 2023 Page 2 You may contact Vanessa Robertson at 202-551-3649 or Kevin Vaughn at 202-551- 3494 if you have questions regarding comments on the financial statements and related matters. Please contact Daniel Crawford at 202-551-7767 or Alan Campbell at 202-551- 4224 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Joan Wu, Esq.
Show Raw Text
United States securities and exchange commission logo
February 14, 2023
Xuezhu Wang
Chief Executive Officer
Happiness Development Group Limited
No. 11, Dongjiao East Road, Shuangxi, Shunchang, Nanping City
Fujian Province, People’s Republic of China
Re:Happiness Development Group Limited
Annual Report on Form 20-F for the Fiscal Year Ended March 31, 2022
Response dated February 8, 2023
File No. 001-39098
Dear Xuezhu Wang:
We have reviewed your February 8, 2023 response to our comment letter and have the
following comment. In our comment, we may ask you to provide us with information so we may
better understand your disclosure.
Please respond to this comment within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe our
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to this comment, we may have additional
comments. Unless we note otherwise, our references to prior comments are to comments in our
February 2, 2023 letter.
Correspondence dated February 8, 2023
Part I
Item 4. Information on the Company
B. Business Overview, page 9
1.We note your response to comment 8 and reissue in part. Please revise your proposed
disclosure to explain why you believe you and your PRC subsidiaries are not required to
obtain permission or approval for the listing or trading of Class A ordinary shares in
foreign stock exchanges from the CSRC.
FirstName LastNameXuezhu Wang
Comapany NameHappiness Development Group Limited
February 14, 2023 Page 2
FirstName LastName
Xuezhu Wang
Happiness Development Group Limited
February 14, 2023
Page 2
You may contact Vanessa Robertson at 202-551-3649 or Kevin Vaughn at 202-551-
3494 if you have questions regarding comments on the financial statements and related
matters. Please contact Daniel Crawford at 202-551-7767 or Alan Campbell at 202-551-
4224 with any other questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Joan Wu, Esq.